Efficacy of combined parenteral meglumine antimoniate and oral allopurinol with meglumine antimoniate alone in treatment of cutaneous leishmaniasis

Jamshida Iqbal Khattak, Dr. Ghafoor Ullah, Col. Qamar uddin Khan


Objective To compare the efficacy of combined parenteral Meglumine Antimoniate and oral Allopurinol with Meglumine Antimoniate alone in the treatment of Cutaneous Leishmaniasis.


Study Design  Randomized controlled trial.


Place and duration of study Department of Dermatology, Combined Military Hospital, Peshawar from May 2016- Oct 2016.


Methods A total of 112 patients presenting with Cutaneous leishmaniasis were included in the study and randomly allocated in two groups. In group I participants received combined therapy with oral allopurinol 15mg/kg/day and parenteral meglumine antimoniate 15mg/kg/day while group II participants received only meglumine antimoniate 15mg/kg/day. Follow up was done at 8th week and results were recorded.


Results  The mean age of the whole study sample was 27.4±4.6 years. In group I the efficacy was observed in 83.9% of patients compared to 73.2% in group II (p 0.167).


Conclusion Our study concluded that the combination therapy (MA plus CL) is more effective in treating CL than isolation therapy with MA alone. More randomized controlled trials with larger sample sizes are highly recommended to draw more conclusive results and generate further evidence for uniform decision making in the treatment of CL.



Cutaneous leishmaniasis; maglumine antimoniate; allopurinol

Full Text:



McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM. 2014;107(1):7–14.

Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S et al. Dressing combined with injection Meglumine Antimoniate in the treatment of cutaneous leishmaniasis. PloS one.2013; 8(6):10

Bari AU. Clinical spectrum of cutaneous leishmaniasis: an overview from Pakistan. Dermatol online J.2012;18(2):4.

Dilnawaz M, Hussain K, Malik NJ, Khan LM,Mazhar H,Soomro AA.Treatment of mucosal and multiple cutaneous leishmaniasis lesions with pentavalent systemic antimony. J Pak Assoc Dermatol. 2015;25(1):40-3.

Salah AB,messaoud NB,Guedri E,zaatour A,Alaya NB,Bettaieb J et al. Topical Paromomycin with or without Gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013; 368:524-532.

Masmoudi A, Hariz W, Marrekchi S, Amouri M,Turk H. Old world cutaneous leishmaniasis: diagnosis and treatment. J Dermatol.2013;7(2):31-41.

de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol.2015;16:99-109.

Masmoudi A, Hariz W, Marrekchi S, Amouri M,Turk H.Old world cutaneous leishmaniasis:diagnosis and treatment. J Dermatol.2013;7(2):31-41.

Monge-Maillo B,Lopez-Velez R.Therapeutic options for Old World cutaneous leishmaniasis and New World cutaneous and mucocutaneous leishmaniasis.Drugs.2013;73:1889-1920.

Ejaz A,Qadir SNU,Bari AU.Comparison of low- dose meglumine antimoniate/Allopurinol combination therapy with full dose meglumine antimoniate alone in the treatment of cutaneous leishmaniasis. J Pak Assoc Dermatol.2014;24(2):108-14.

Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low dose meglumine antimoniate. Int J Dermatol. 2002; 41:44

Ashford RW, Jarry DM. Epide´miologie des leishmanioses de l’Ancien Monde. In: Dedet JP, editor. Les leishmanioses. Paris: Ellipses; 1999. p. 131–46.

Dedet JP. Epide´miologie des leishmanioses du Nouveau Monde. In: Dedet JP, editor. Les leishmanioses. Paris: Ellipses; 1999. p.147–60.

Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561–77.

Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 2005;5:763–74.

Minodier P, Retornaz K, Horelt A, Garnier JM. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fund Clin Pharmacol 2003;17:183–8.

World Health Organization. The leishmaniases. WHO technical report series, vol. 701. Geneva:WHO;1984.

Momeni AZ, Aminjavaheri M. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. European J Dermatol. 2002;13(1):40-3.

Grevelink SA, Lcrner EA. Leishmaniasis. J Am Acad Dermatol 1996;34: 257–72.

Grogl M, Thomason TN, Frune ED. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992;47:117–26.

Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993;9:323–8.

Chunge CN, Gachihi G, Muigai R. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg. 1985;79:715–8.

Berens RL, Marr JJ, Nelson DJ. Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani. Biochem Pharmacol 1980;29:2397–8.

Marr JJ, Berens RL, Nelson DJ. Antileishmanial action of 4-thiopyrazolo(3,4-D) pyrimidine and its ribonucleoside. Biochem Pharmacol 1982;31:143–8.

Lafon SW, Nelson DJ, Berens RL. Inosine analogs: their metabolism in mouse cells and in Leishmania donovani. J Biol Chem 1985;260:9660–5.

Martinez S, Looker DL, Berens RL. The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis. Am J Trop Med Hyg 1988;39:250–5.

Shokri A, Sharifi I, Khamesipour A, Nakhaee N, Fasihi Harandi M, Nosratabadi J, et al. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res. 2012;110(3):1113–7.

Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev.2006;19(1):111–26.

Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007;46(8):848-52.

Deps PD, Viana MC, Falqueto A, Dietze R. Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev Soc Bras Med Trop.2000;33(6):535-43.


  • There are currently no refbacks.

ISSN: 1560-9014